Search Results - seth+ludwig

3 Results

Sort By:

Multispecific Antibodies that Induce Downregulation of Programmed Death-ligand 1

Unmet Need: It is estimated that in 2018 there were more than 17 million new cases of cancer worldwide (see ACS). Immune checkpoint therapies have become a powerful treatment route for a wide variety of cancer types and have increased the life expectancy for patients whose disease is refractory to all other therapies. Due to variability in patient response...

Published: 3/14/2025 | Inventor(s): Jamie Spangler, Seth Ludwig, Angela Zhu, Rakeeb Kureshi, Helen Dooley

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Antibodies

Engineered Cytokine-antibody Fusion for Targeted Expansion of Immune Effector Cells

Unmet NeedGlobal revenue from the cytokine therapeutics market was valued at approximately $16.5 billion in 2018, and cytokine immunotherapy is a promising field of anti-cancer treatments for a broad range of cancer types. In particular, interleukin-2 (IL-2) therapy is shown to stimulate anti-cancer immunity. However, IL-2 activates contradictory immune...

Published: 3/14/2025 | Inventor(s): Jamie Spangler, Jakub Tomala, Michael Leff, Seth Ludwig, Elissa Leonard, Marek Kovar, Jirina Kovarova

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics

A Platform to Improve Metabolic Glycoengineering in Biomanufacturing

Unmet Need: Methods to control glycosylation, a critical post-translational modification of therapeutic proteins, now focus on maintaining conventional glycosylation profiles. Strict adherence to naturally-occurring glycosylation patterns, however, hinders and in some cases precludes the development of novel protein therapeutics required for rare diseases...

Published: 3/14/2025 | Inventor(s): Kevin Yarema, Christian Agatemor, Christopher Saeui, Matthew Buettner, Jamie Spangler, Seth Ludwig, Zachary Bernstein, Kris Dammen-Brower, Riddhima Deenar Chitre

Keywords(s):

Category(s): Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Industrial Tech